Market Trends in Parenteral Administration
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Market Trends in Parenteral Administration

Pharma Tech Outlook | Tuesday, March 29, 2022

Growing pipeline of biologics and COVID vaccine production drive unprecedented growth.

FREMONT, CA: With today's rising pipeline of biologics, such as sophisticated oncology products administered parenterally and COVID vaccine production, there is a growing requirement for technically advanced manufacturing support, which contract development and manufacturing organizations (CDMOs) play an essential part in. To assure product quality and safety, biologics require unique methods and equipment for fill-finish operations, necessitating the development of adaptable aseptic fill-finish technologies. With biologics accounting for the bulk of top-selling pharmaceuticals and the fastest-growing pharmaceutical category, CDMOs that specializes in aseptic fill-finish for injectable therapies are playing an increasingly important strategic role. This article discusses the parenteral and fill-finish manufacturing markets and potential and recent investments.

According to a market research analysis by Fact, the parenteral medicines market is expected to reach a startling valuation of USD 802 billion by the end of the forecast period, according to a market research analysis by Fact.MR titled Parenteral Drugs Market Forecast, Trend Analysis, and Competition Tracking - Global Market Insights 2019 to 2029. According to the research, this is due to rising spending on biologics, the requirement for a speedier way of drug administration, a growing desire for single-dose vaccines and pharmaceuticals, and an increase in the number of local manufacturers.

Fill-finish is the final and most critical step in the drug manufacturing process. It involves aseptic filling of biologic drugs or medicines, such as sterile liquid, powder, and suspension, in vials, ampoules, bottles, syringes, and cartridges, following upstream bioprocessing and downstream purification. According to a study by The Insight Partners titled "Fill Finish Manufacturing Market Forecast to 2027 – COVID-19 Impact and Global Analysis – By Product, End User," the fill-finish manufacturing market was valued at USD 6.1 billion in 2019 and is expected to reach

USD 12.5 billion by 2027, growing at a CAGR of 9.6 percent from 2020 to 2027. The market is being driven by the introduction of prefilled syringes for parenteral administration and the growing demand for biologics.

The Vice President of Parenteral Services, Alcami, remarked that Alcami and other top five most active global sterile drug product contract manufacturers based in the US and EU had been significantly investing in expanding isolator-based fill-finish capacity for both vials and syringes. These expenditures were required to address the rapidly increasing demand for parenteral pharmaceuticals, as well as growing regulatory needs that all sterile manufacturing lines use isolator technology to reduce the risk of patient safety during the manufacturing process.

Weekly Brief

Read Also